By contrast, insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) was also identified as a promising CPA in our screen, showing relatively high prevalence of expression in ~15 different cancer types, including glioblastoma, uterine, testicular, and lung cancers (Fig. 3). This evidence concerns the gene IGF2BP3 and lung carcinoma.